- Genprex (NASDAQ: GNPX) to present Acclaim-3 clinical trial design at the 2025 ASCO Annual Meeting.
- The trial evaluates Reqorsa® Gene Therapy in combination with Tecentriq® for extensive stage small cell lung cancer (ES-SCLC).
- Presentation scheduled for May 31, 2025, from 1:30 to 4:30 p.m. CT in Chicago.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, has been selected to present the Acclaim-3 Phase 1/2 clinical trial design at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will showcase its Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® as a maintenance therapy for treating extensive stage small cell lung cancer (ES-SCLC). The presentation is a significant opportunity for Genprex to highlight its innovative approach to cancer treatment development.
The presentation is scheduled for May 31, 2025, from 1:30 to 4:30 p.m. CT and will be delivered by Dr. Bo Wang from the Oncology Associates of Oregon. The abstract will be featured in the Trials in Progress poster session, marking an important milestone in the company's efforts to advance its gene therapy technologies.
Genprex's participation in the ASCO Annual Meeting underscores industry recognition of its work in developing novel therapeutic approaches for cancer. With a focus on providing new treatment options for large patient populations, Genprex continues to work with world-class institutions and collaborators to enhance its pipeline of gene therapies.
